Semtech Corporation (Nasdaq: SMTC) has delivered better-than-expected results in the first quarter of fiscal 2024, reporting earnings per share (EPS) of $0.02, surpassing the consensus estimate of a loss of $0.08 per share. 

Looking ahead to the second quarter of fiscal 2024, the company anticipates a range of performance between a loss of $0.02 per share and earnings of $0.06 per share, which exceeds the consensus estimate of a loss of $0.02 per share for the period. 

$SMTC was trading at $27.56 in after-hours, experiencing a notable increase of $5.13 or approximately 22.87%

4D Molecular Therapeutics, Inc.? (Nasdaq: FDMT) has shared promising interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial, targeting the treatment of cystic fibrosis lung disease. 

The trial focuses on utilizing 4D-710, a carefully designed combination of the company's advanced vector, A101, and a genetically optimized CFTR?R transgene. The therapy is specifically engineered for aerosol delivery to facilitate CFTR expression within lung airway epithelial cells. 

The initial cohort of participants, who were either ineligible for or intolerant of existing CFTR modulators, received a dose of 4D-710 (1E15 vg) and demonstrated meaningful improvements in their quality of life as assessed by CFQ-R-R (Cystic Fibrosis Questionnaire-Revised respiratory symptom score). Additionally, their ppFEV1 (percent predicted forced expiratory volume in one second) either improved or remained stable.

This positive development has led to an optimistic market response in after-hours, with $FDMT trading at $21.50, up $3.23 or approximately 17.68%.

Celsius Holdings, Inc. (Nasdaq: CELH), a leading global company in the functional beverage industry, has received a price target increase from Stifel, raising it from $129 to $155. 

With $CELH closing at $138.03 on Wednesday, this adjusted price target suggests a potential upside of approximately $16.97 or around 12.29%, as per Stifel's analysis.

Alkermes plc (Nasdaq: ALKS), a biopharmaceutical company specializing in the development and commercialization of innovative medicines, has also seen its price target raised by Piper Sandler, increasing it from $35 to $37. 

Based on Wednesday's closing price of $31.05, this adjusted price target implies a potential upside of approximately $5.95 or around 19.16% for $ALKS, according to Piper Sandler's view.

Please note that the potential upside figures mentioned above are based on the opinions and views of the respective brokerage firms, investment firms, or analysts. 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)